InvestSMART

Immutep Limited (ASX: IMM) - Announcements

Current share price for IMM : $0.022 0.001 (4.35%)+

ASX company news and announcements for Immutep Limited (IMM) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Immutep Limited (IMM) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Immutep Limited (IMM), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Immutep Limited (IMM)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$32 Application for quotation of securities - IMM 25 Jun 2021 11:39AM $0.545 $0.022 fallen by 95.96%
$32 Efti to be evaluated in new triple combination therapy trial 21 Jun 2021 9:48AM $0.615 $0.022 fallen by 96.42%
$32 Proposed issue of securities - IMM 21 Jun 2021 9:48AM $0.615 $0.022 fallen by 96.42%
$32 Immutep Capital Raising Presentation 21 Jun 2021 9:47AM $0.615 $0.022 fallen by 96.42%
$32 Immutep secures commitments for A$60 million in a Placement 21 Jun 2021 9:47AM $0.615 $0.022 fallen by 96.42%
$32 Trading Halt 17 Jun 2021 8:20AM $0.615 $0.022 fallen by 96.42%
$32 Change in substantial holding 15 Jun 2021 8:17AM $0.625 $0.022 fallen by 96.48%
$32 Immutep global webcast slides 9 Jun 2021 7:21PM $0.615 $0.022 fallen by 96.42%
$32 Appendix 2A 8 Jun 2021 4:11PM $0.640 $0.022 fallen by 96.56%
$32 Immutep Reveals a New anti-LAG-3 Research Program 8 Jun 2021 7:37AM $0.655 $0.022 fallen by 96.64%
$32 Application for quotation of securities - IMM 7 Jun 2021 4:01PM $0.655 $0.022 fallen by 96.64%
$32 Immutep presentation for Jefferies Healthcare Conference 4 Jun 2021 4:19PM $0.665 $0.022 fallen by 96.69%
$32 Immutep Reports Positive Data from its TACTI-002 ph 2 trial 4 Jun 2021 4:17PM $0.665 $0.022 fallen by 96.69%
$32 Immutep Reports Positive Final Data from INSIGHT-004 trial 4 Jun 2021 4:14PM $0.665 $0.022 fallen by 96.69%
$32 Immutep granted European patent for its LAG-3 candidate Efti 2 Jun 2021 11:13AM $0.685 $0.022 fallen by 96.79%
$32 Immutep enters New Collaboration with Merck KGaA for Efti 1 Jun 2021 8:20AM $0.700 $0.022 fallen by 96.86%
$32 Immutep granted Chinese patent for its LAG-3 candidate Efti 26 May 2021 1:32PM $0.605 $0.022 fallen by 96.36%
$32 Immutep to present at Jefferies Healthcare Conference 25 May 2021 8:16AM $0.565 $0.022 fallen by 96.11%
$32 TACTI-002 and INSIGHT-004 abstracts for ASCO 2021 20 May 2021 1:07PM $0.555 $0.022 fallen by 96.04%
$32 Change in substantial holding 20 May 2021 8:22AM $0.505 $0.022 fallen by 95.64%
$32 Change in substantial holding 18 May 2021 8:20AM $0.450 $0.022 fallen by 95.11%
$32 Appendix 2A 14 May 2021 10:55AM $0.455 $0.022 fallen by 95.16%
$32 Immutep Corporate Presentation 13 May 2021 11:51AM $0.465 $0.022 fallen by 95.27%
$32 Operational Update 7 May 2021 9:49AM $0.430 $0.022 fallen by 94.88%
$32 TACTI-002 & INSIGHT-004 data to be presented at ASCO 29 Apr 2021 7:31AM $0.430 $0.022 fallen by 94.88%

476 - 500 of 798 results

Page 20 of 32

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.